1. History
- Key HPI questions: Onset, duration, and severity of dysuria, urinary frequency, urgency, suprapubic pain, and hematuria [1-2]
- Symptom characterization: Burning/pain with urination (internal vs. external), sense of incomplete emptying, nocturia, gross hematuria, urine cloudiness or odor
- Timing/triggers: Relationship to sexual intercourse, new sexual partner, spermicide/diaphragm use, recent antibiotic use, recent catheterization or instrumentation [3]
- Associated symptoms: Vaginal discharge or irritation (suggests vaginitis/STI rather than cystitis), back/flank pain, fever, nausea/vomiting (suggests pyelonephritis) [1]
- Important negatives: Absence of vaginal discharge raises probability of cystitis to >90% in women with dysuria and frequency. Absence of fever, chills, and flank pain helps exclude upper tract involvement [1][4]
2. Alarm Features
- Fever (>38°C), chills, rigors, or hemodynamic instability → suspect pyelonephritis or urosepsis [1][4]
- Flank pain or costovertebral angle (CVA) tenderness → upper tract infection [4-5]
- Nausea/vomiting with urinary symptoms → pyelonephritis [1]
- Urinary retention or inability to void → urinary obstruction requiring same-day in-person evaluation [6]
- Pregnancy → all UTIs require culture-confirmed diagnosis and treatment; risk of ascending infection and preterm labor [5]
- Immunocompromised patients, recent urologic procedures, or indwelling catheters → complicated UTI pathway [4]
3. Medications
First-line empiric treatment (per IDSA/ACP guidelines): [7-8]
- Nitrofurantoin 100 mg BID × 5 days (most effective in recent head-to-head data) [9]
- TMP-SMX 160/800 mg BID × 3 days (if local resistance <20%) [8]
- Fosfomycin 3 g single dose (inferior efficacy vs. nitrofurantoin per SCOUT trial) [9]
- Pivmecillinam 400 mg TID × 3 days (FDA-approved in the US for uncomplicated UTI in women) [9-10]
Contraindicated/avoid
- Fluoroquinolones: Not recommended empirically for uncomplicated cystitis due to adverse effect profile (tendinopathy, QTc prolongation, aortic dissection risk, C. difficile); reserve for resistant organisms [11-12]
- Nitrofurantoin: Avoid if CrCl <30 mL/min; not effective for upper tract infections (poor renal parenchymal penetration)
- TMP-SMX: Avoid if local E. coli resistance >20% [8]
Medication cautions
- Nitrofurantoin: Pulmonary toxicity with prolonged use; avoid in G6PD deficiency
- Fosfomycin: Not recommended for non-E. coli ESBL infections (e.g., K. pneumoniae carries fosA gene) [12]
4. Diet
- Increased fluid intake: ≥1.5 L/day recommended for symptom relief and prevention of recurrence [2]
- Cranberry products: Evidence supports a role in prevention of recurrent UTI, not treatment of acute episodes [2]
- Avoid bladder irritants during acute episode: caffeine, alcohol, spicy foods, artificial sweeteners
- Long-term: Adequate hydration is the most evidence-supported dietary intervention for recurrence prevention
5. Review of Systems
- GU: Dysuria, frequency, urgency, hematuria, suprapubic pain, nocturia, vaginal discharge/irritation, urethral discharge (men)
- Constitutional: Fever, chills, rigors, malaise, fatigue
- GI: Nausea, vomiting, diarrhea (may suggest alternative diagnosis or systemic illness) [6]
- MSK/Back: Flank pain, CVA tenderness (pyelonephritis)
- GYN: Vaginal discharge, dyspareunia, vulvar lesions (vaginitis, STI)
- Neuro (elderly): New confusion or altered mental status may be the only presenting symptom in frail elderly patients
6. Collateral History and Family History
- Prior UTI history: Number of episodes, prior organisms and sensitivities, prior treatment failures
- Sexual history: New partners, contraceptive method (spermicide/diaphragm increase risk), STI risk factors [1]
- Menopausal status: Genitourinary syndrome of menopause (GSM) can mimic and predispose to UTI [6]
- Family history: Recurrent UTI in first-degree relatives may indicate genetic susceptibility
- Social context: Access to timely urine testing, barriers to follow-up (relevant for triage decisions) [6]
7. Risk Factors
- Female sex: 50× more common than in males; 40–50% of women experience ≥1 UTI in their lifetime [3]
- Sexual intercourse (strongest modifiable risk factor in premenopausal women) [1]
- Spermicide/diaphragm use [1]
- Prior UTI history [2]
- Postmenopausal status: Vaginal atrophy, loss of lactobacilli [6]
- Diabetes mellitus [13]
- Urinary catheterization or recent instrumentation [4]
- Urologic abnormalities: Obstruction, neurogenic bladder, vesicoureteral reflux
- Antibiotic use: Recent antibiotics increase risk of resistant organisms [6]
- Immunosuppression [14]
8. Differential Diagnosis
The following table from the AAFP summarizes key differentiating features: [2]
9. Past Medical History
- Prior UTIs: Frequency, organisms, resistance patterns, treatment responses
- Recurrent UTI (≥2 in 6 months or ≥3 in 12 months): Warrants in-person evaluation and culture-guided therapy [2][6]
- Urologic surgery or instrumentation
- Diabetes, immunosuppression, pregnancy
- Neurogenic bladder, urinary retention, structural abnormalities
- Kidney stones
- Allergies: Sulfa allergy (precludes TMP-SMX), nitrofurantoin hypersensitivity
10. Physical Exam
- Vital signs: Temperature (fever >38°C → pyelonephritis), heart rate, blood pressure (tachycardia/hypotension → sepsis)
- Abdominal exam: Suprapubic tenderness (supports cystitis); distended bladder (retention)
- CVA tenderness: The only physical exam finding that increases the probability of UTI — specifically indicates pyelonephritis [1]
- Pelvic exam (if vaginal symptoms present): Evaluate for discharge, cervicitis, vulvar lesions, vaginal atrophy [15]
- DRE (men): Prostatic tenderness/edema suggests prostatitis [17]
- Genital exam (men): Testicular tenderness/swelling (epididymo-orchitis)
11. Lab Studies
- Urinalysis (dipstick):
- Leukocyte esterase: Sensitivity ~81–83%, specificity ~67–71% [17]
- Nitrites: Sensitivity ~55–58%, specificity ~90–98% [5][17]
- Combined LE or nitrite positive: Sensitivity 75%, specificity 82% [1]
- If both LE and nitrite negative, UTI is unlikely (NPV 78–98%) [5]
- Urine culture: Not required for uncomplicated cystitis in women with classic symptoms. Indicated for: recurrent UTI, treatment failure, resistant organisms, atypical presentation, all men, pregnant patients, elderly [1-2][6]
- CBC, BMP, blood cultures: Only if systemic illness suspected (fever, sepsis, pyelonephritis) [5]
- STI testing: Gonorrhea/chlamydia NAAT if risk factors present [17]
12. Imaging
- Not indicated for uncomplicated cystitis [2]
- Renal ultrasound: Consider if urinary obstruction, abscess, or structural abnormality suspected
- CT abdomen/pelvis: If nephrolithiasis, renal abscess, or emphysematous pyelonephritis suspected
- Important: Imaging should be reserved for complicated presentations, recurrent infections without clear cause, or failure to respond to appropriate therapy
13. Special Tests
- Urine dipstick: Point-of-care test; most useful when clinical picture is ambiguous. Adds little when history is strongly suggestive of UTI [1]
- Post-void residual (bladder scan): If urinary retention suspected [17]
- Cystoscopy: Not indicated acutely; consider for recurrent UTI, persistent hematuria after infection resolves, or suspected structural pathology
- Methenamine hippurate: Effective for recurrent UTI prevention (not a diagnostic test, but a notable preventive intervention) [2]
14. ECG
- Not routinely indicated for cystitis
- Consider if prescribing fluoroquinolones (risk of QTc prolongation) in patients with cardiac risk factors [12]
- Obtain ECG if sepsis or hemodynamic instability is present
15. Assessment
Clinical summary: Acute cystitis is a clinical diagnosis in women with classic symptoms (dysuria, frequency, urgency) without vaginal discharge. The probability exceeds 90% when dysuria and frequency are present without vaginal symptoms. [1] Most cases (80%) are caused by E. coli. [3]
Severity stratification
- Uncomplicated: Symptoms confined to the bladder, no systemic signs, in a non-pregnant, non-catheterized adult without urologic abnormalities [4]
- Complicated: Fever, flank pain, CVA tenderness, systemic illness, or presence of complicating factors (catheter, obstruction, pregnancy, immunosuppression) [4]
Atypical presentations: Elderly patients may present with confusion or functional decline without classic urinary symptoms. Men with cystitis symptoms should be evaluated for prostatitis and urethritis. [2][17]
Complications: Pyelonephritis (1–2% of untreated cases), urosepsis, renal abscess (rare)
16. Treatment Plan
Initial management — uncomplicated cystitis in women: [7-9]
Men: 7-day course of TMP-SMX or nitrofurantoin; always obtain urine culture [2]
Symptomatic relief: NSAIDs (ibuprofen) for pain; phenazopyridine 200 mg TID × 2 days for dysuria (warn about orange urine discoloration)
Delayed antibiotic strategy: In select low-risk women who prefer to avoid antibiotics, a backup prescription to fill if symptoms do not improve in 48–72 hours is a reasonable option [2]
Recurrence prevention: Adequate hydration (≥1.5 L/day), cranberry products, methenamine hippurate, topical vaginal estrogen in postmenopausal women [2][6]
17. Disposition
- Discharge (vast majority): Uncomplicated cystitis is managed entirely as an outpatient [2][13]
- Same-day in-person evaluation: Symptoms of pyelonephritis, complicated cystitis, or urinary obstruction [6]
- Admission criteria: Sepsis, hemodynamic instability, intractable vomiting (unable to tolerate oral antibiotics), severe pyelonephritis, immunocompromised with systemic illness, pregnant with pyelonephritis [5]
- Observation: Consider for borderline cases (e.g., early pyelonephritis responding to IV fluids and parenteral antibiotics)
- Specialist consultation: Urology referral for recurrent UTI (≥3/year), structural abnormalities, persistent hematuria after infection resolution, suspected obstruction [6]
18. Follow Up / Return Precautions
- Follow-up timing: Routine follow-up not needed if symptoms resolve. If symptoms persist beyond 48–72 hours of appropriate antibiotics, reassess and obtain urine culture [2]
- Return immediately for: Fever >38°C, rigors, flank pain, vomiting, inability to tolerate oral medications, worsening symptoms, signs of urinary retention
- Patient counseling:
- Complete the full antibiotic course
- Increase fluid intake
- Symptoms typically improve within 24–48 hours of starting antibiotics
- Phenazopyridine is for symptom relief only, not treatment
- Expected recovery: Most uncomplicated cases resolve within 3–5 days of treatment [2][9]
- Recurrent UTI: If ≥2 episodes in 6 months or ≥3 in 12 months, warrants at least one in-person evaluation with physical exam to assess for treatable underlying conditions (e.g., genitourinary syndrome of menopause) [6]
The following algorithm from the Ann Arbor Guide illustrates the triage approach for nonpregnant women with suspected UTI, including when empiric antibiotics, urine testing, and in-person evaluation are appropriate:
References
1. Uncomplicated Urinary Tract Infection. — Hooton TM. The New England Journal of Medicine. 2012.
2. Acute Uncomplicated UTIs in Adults: Rapid Evidence Review. — Kurotschka PK, Gágyor I, Ebell MH. American Family Physician. 2024.
3. Reappraisal of the Treatment Duration of Antibiotic Regimens for Acute Uncomplicated Cystitis in Adult Women: A Systematic Review and Network Meta-Analysis of 61 Randomised Clinical Trials. — Kim DK, Kim JH, Lee JY, et al. The Lancet. Infectious Diseases. 2020.
4. Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Introduction and Methods. — Barbara W. Trautner, Nicolás W. Cortés-Penfield, Kalpana Gupta, et al Infectious Diseases Society of America. 2025.
5. Urinary Tract Infections in Pregnant Individuals. — Committee on Clinical Consensus—Obstetrics Obstetrics and Gynecology. 2023.
6. Ann Arbor Guide to Triaging Adults With Suspected Urinary Tract Infection for In-Person and Telehealth Settings. — Meddings J, Chrouser K, Fowler KE, et al. JAMA Network Open. 2026.
7. Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians. — Lee RA, Centor RM, Humphrey LL, et al. Annals of Internal Medicine. 2021.
8. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. — Gupta K, Hooton TM, Naber KG, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2011.
9. Clinical and Bacteriological Effectiveness of Three Different Short-Course Antibiotic Regimens and Single-Dose Fosfomycin for Uncomplicated Lower Urinary Tract Infections in Women (SCOUT): A Pragmatic, Multicentre, Open-Label, Randomised Clinical Trial. — Llor C, Monfà R, Garcia-Sangenís A, et al. Lancet. 2026.
10. FDA Orange Book. — FDA Orange Book. 2026.
11. Antibiotic Courses for Common Infections: Recommendations From the ACP. — Dakkak M, Sabharwal M. American Family Physician. 2022.
12. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. — Tamma PD, Aitken SL, Bonomo RA, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2023.
13. Diagnosis and Management of Urinary Tract Infections in the Outpatient Setting: A Review. — Grigoryan L, Trautner BW, Gupta K. The Journal of the American Medical Association. 2014.
14. Non-Steroidal Anti-Inflammatory Drugs for Treating Symptomatic Uncomplicated Urinary Tract Infections in Non-Pregnant Adult Women. — Sachdeva A, Rai BP, Veeratterapillay R, Harding C, Nambiar A. The Cochrane Database of Systematic Reviews. 2024.
15. Dysuria: Evaluation and Differential Diagnosis in Adults. — Michels TC, Sands JE. American Family Physician. 2015.
16. Symptoms of Interstitial Cystitis, Painful Bladder Syndrome and Similar Diseases in Women: A Systematic Review. — Bogart LM, Berry SH, Clemens JQ. The Journal of Urology. 2007.
17. Prostatitis. — Borgert BJ, Wallen EM, Pham MN. The Journal of the American Medical Association. 2025.